Assessing HER2 amplification in breast cancer: Findings from the Australian In Situ Hybridization Program

Breast Cancer Research and Treatment

Volumn 134, Issue 2, 2012, Pages 617-624

  Bilous, Michael ^a,b   Morey, Adrienne L ^c   Armes, Jane E ^d   Bell, Richard ^e   Button, Peter H ^f   Cummings, Margaret C ^g   Fox, Stephen B ^h   Francis, Glenn D ^g,i,j,k   Waite, Brigid ^l   McCue, Glenda ^m   Raymond, Wendy A ^n,o   Robbins, Peter D ^p   Farshid, Gelareh ^q  

^a Norwest Private Hospital   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d MATER HOSPITAL   (Australia)

^e Andrew Love Cancer Centre   (Australia)

^f Mezzanine Level   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^j PRINCESS ALEXANDRA HOSPITAL   (Australia)

^k GRIFFITH UNIVERSITY   (Australia)

^l Roche Products Pty Limited   (Australia)

^m Woolomin Consulting   (Australia)

ⁿ Healthscope Pathology   (Australia)

^o FLINDERS MEDICAL CENTRE   (Australia)

^p PATHWEST LABORATORY MEDICINE   (Australia)

^q SA Pathology   (Australia)

more..

Author keywords

Breast cancer; HER2 genes; Immunohistochemistry; In situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; AUSTRALIA; BREAST CANCER; CANCER DIAGNOSIS; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; LABORATORY TEST; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUALITY CONTROL; SILVER IN SITU HYBRIDIZATION;

AUSTRALIA; BREAST NEOPLASMS; DIAGNOSTIC ERRORS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; RECEPTOR, ERBB-2;

EID: 84868200630     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2093-6     Document Type: Article

References (30)

1. Francis GD, Jones MA, Beadle GF et al (2009) Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (≥ISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 18:88-95
2. Gown AM, Goldstein LC, Barry TS et al (2008) High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 21:1271-1277
3. Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598-6607
4. Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63-69
5. Konecny G, Pauletti G, Pegram M et al (2003) Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142-153
6. Penault-Llorca F, Ettore F, Antoine M et al (2006) Comparison of immuno-histochemistry and fluorescence in situ hybridisation techniques for determination of the HER2 gene status of patients with metastatic breast cancer in France: final results of the FISH 2002 study. Poster 5016 presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, 14-17 Dec. 2006
7. Baselga J, Carbonell X, Castañeda-Soto N-J et al (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23:2162-2171
8. Eiermann W, on behalf of the International Herceptin Study Group (2001) Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol 12(suppl 1):S57-S62
9. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265-4274
10. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
11. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726
12. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820
13. Perez EA, Romond EH, Suman VJ et al (2007) Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol (Meeting Abstracts) 25(suppl 6):512
14. Slamon D, Eiermann W, Robert N et al (2006) Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. Oral presentation at the 29th San Antonio Breast Cancer Symposium, San Antonio, 14-17 Dec. 2006
15. Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29-36
16. National Comprehensive Cancer Network (2010) NCCN clinical practice guidelines in oncology: breast cancer V.1.2012. http://www.nccn.org/ professionals/physician-gls/PDF/breast.pdf
17. Bast RC Jr, Ravdin P, Hayes DF et al (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878
18. Wolff AC, Hammond MEH, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145
19. Paik S, Bryant J, Tan-Chiu E et al (2002) Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854
20. Perez EA, Suman VJ, Davidson NE et al (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032-3038
21. Reddy JC, Reimann JD, Anderson SM et al (2006) Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 7:153-157
22. Farshid G, Armes JE, Bell R et al (2010) Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice. Diagn Mol Pathol 19:187-193
23. Weisgerber-Kriegl U, Cirrincione A, McNiven P (2008) Estimation of the epidemiological effect of trastuzumab over 10 years in 5 European countries. Poster 6589 presented at the 44th ASCO Annual Meeting, Chicago, 30-3 May-June 2008
24. Yaziji H, Goldstein LC, Barry TS et al (2004) HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972-1977
25. Cabioglu N, Sahin AA, Morandi P et al (2009) Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20:1013-1019
26. Emi Y, Kitamura K, Shikada Y et al (2002) Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery 131(Suppl 1):S217-S221
27. Sauter G, Lee J, Bartlett JM et al (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323-1333
28. Vranic S, Teruya B, Repertinger S et al (2011) Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117:48-53
29. Perez EA, Reinholz MM, Hillman DW et al (2010) HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28:4307-4315
30. Shousha S, Peston D, Amo-Takyi B et al (2009) Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 54:248-253